ATROVENT HFA
SAMA MDI
Ipratropium bromide · Boehringer Ingelheim
Active Medication & Mechanism
- Ipratropium bromide SAMA17 mcg per actuation
Short-acting muscarinic antagonist (anticholinergic). Blocks vagally mediated reflexes by antagonizing M3 receptors on bronchial smooth muscle, inhibiting bronchoconstriction and mucus secretion.
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 17 mcg | Adults (≥18 years) | 2 inhalations four times a day Maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Maximum 12 inhalations in 24 hours. | 136 mcg (8 inhalations) | FDA Approved |
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Atrovent HFA is not indicated for asthma, though it may be used off-label. Not FDA-approved for asthma. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved ATROVENT HFA is not indicated for initial treatment of acute bronchospasm requiring rapid-response rescue therapy. |